Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view
Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent metabolic disorder with steadily increasing incidence rates worldwide, especially in the West. There are no drugs available at present to treat NAFLD, and the primary therapeutic options include weight loss and the combination of health...
Saved in:
| Published in | World journal of gastroenterology : WJG Vol. 26; no. 16; pp. 1901 - 1911 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Baishideng Publishing Group Inc
28.04.2020
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent metabolic disorder with steadily increasing incidence rates worldwide, especially in the West. There are no drugs available at present to treat NAFLD, and the primary therapeutic options include weight loss and the combination of healthy diet and exercise. Therefore, novel interventions are required that can target the underlying risk factors. Gut microbiota is an "invisible organ" of the human body and vital for normal metabolism and immuno-modulation. The number and diversity of microbes differ across the gastrointestinal tract from the mouth to the anus, and is most abundant in the intestine. Since dysregulated gut microbiota is an underlying pathological factor of NAFLD, it is a viable therapeutic target that can be modulated by antibiotics, probiotics, prebiotics, synbiotics, fecal microbiota transplantation, and microbial metabolites. In this review, we summarize the most recent advances in gut microbiota-targeted therapies against NAFLD in clinical and experimental studies, and critically evaluate novel targets and strategies for treating NAFLD. |
|---|---|
| AbstractList | Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent metabolic disorder with steadily increasing incidence rates worldwide, especially in the West. There are no drugs available at present to treat NAFLD, and the primary therapeutic options include weight loss and the combination of healthy diet and exercise. Therefore, novel interventions are required that can target the underlying risk factors. Gut microbiota is an “invisible organ” of the human body and vital for normal metabolism and immuno-modulation. The number and diversity of microbes differ across the gastrointestinal tract from the mouth to the anus, and is most abundant in the intestine. Since dysregulated gut microbiota is an underlying pathological factor of NAFLD, it is a viable therapeutic target that can be modulated by antibiotics, probiotics, prebiotics, synbiotics, fecal microbiota transplantation, and microbial metabolites. In this review, we summarize the most recent advances in gut microbiota-targeted therapies against NAFLD in clinical and experimental studies, and critically evaluate novel targets and strategies for treating NAFLD. Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent metabolic disorder with steadily increasing incidence rates worldwide, especially in the West. There are no drugs available at present to treat NAFLD, and the primary therapeutic options include weight loss and the combination of healthy diet and exercise. Therefore, novel interventions are required that can target the underlying risk factors. Gut microbiota is an "invisible organ" of the human body and vital for normal metabolism and immuno-modulation. The number and diversity of microbes differ across the gastrointestinal tract from the mouth to the anus, and is most abundant in the intestine. Since dysregulated gut microbiota is an underlying pathological factor of NAFLD, it is a viable therapeutic target that can be modulated by antibiotics, probiotics, prebiotics, synbiotics, fecal microbiota transplantation, and microbial metabolites. In this review, we summarize the most recent advances in gut microbiota-targeted therapies against NAFLD in clinical and experimental studies, and critically evaluate novel targets and strategies for treating NAFLD.Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent metabolic disorder with steadily increasing incidence rates worldwide, especially in the West. There are no drugs available at present to treat NAFLD, and the primary therapeutic options include weight loss and the combination of healthy diet and exercise. Therefore, novel interventions are required that can target the underlying risk factors. Gut microbiota is an "invisible organ" of the human body and vital for normal metabolism and immuno-modulation. The number and diversity of microbes differ across the gastrointestinal tract from the mouth to the anus, and is most abundant in the intestine. Since dysregulated gut microbiota is an underlying pathological factor of NAFLD, it is a viable therapeutic target that can be modulated by antibiotics, probiotics, prebiotics, synbiotics, fecal microbiota transplantation, and microbial metabolites. In this review, we summarize the most recent advances in gut microbiota-targeted therapies against NAFLD in clinical and experimental studies, and critically evaluate novel targets and strategies for treating NAFLD. |
| Author | Xu, Hao-Ming Li, Yong-Qiang Chen, Hui-Ting Huang, Hong-Li Zhou, Yong-Jian |
| Author_xml | – sequence: 1 givenname: Hui-Ting surname: Chen fullname: Chen, Hui-Ting – sequence: 2 givenname: Hong-Li surname: Huang fullname: Huang, Hong-Li – sequence: 3 givenname: Yong-Qiang surname: Li fullname: Li, Yong-Qiang – sequence: 4 givenname: Hao-Ming surname: Xu fullname: Xu, Hao-Ming – sequence: 5 givenname: Yong-Jian surname: Zhou fullname: Zhou, Yong-Jian |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32390701$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kTtPwzAUhS1UREthZ0IZWVL8apwwIFWIl1SJpcyWY99QV2lcbDeIf48rCgIkJg_3O-dc33OMBp3rAKEzgidM8PLybfUy6WkxsaSYkAqTAzSilFQ5LTkeoBHBWOQVo2KIjkNYYUwZm9IjNGSUVVhgMkLPiyV4tYFttDpTpledhpDZLktJuWq1W7o2TRoV43vW2h58ZmwAFeAqm2Vrq72rrYsq19BF8GCy3sLbCTpsVBvgdP-O0eLudnHzkM-f7h9vZvNc84LGHAwXqiFNRSjnpia4rAUXVVWIBjjHjeGmmooprXn6BBHABddQMqVLQ8qiZmN0_Wm72dZrMLsVvGrlxtu18u_SKSt_Tzq7lC-ul4JiQpLpGF3sDbx73UKIcm2DhrZVHbhtkJQnjpSs5Ak9_5n1HfJ1ygTgTyCdJAQPzTdCsNy1JVNbMrUlU1ty11aSFH8k2kYVrdtta9v_hR_yvZxO |
| CitedBy_id | crossref_primary_10_3390_nu13051442 crossref_primary_10_3390_ijms23137457 crossref_primary_10_1016_j_biopha_2024_116223 crossref_primary_10_1038_s41429_022_00522_w crossref_primary_10_1097_MD_0000000000033147 crossref_primary_10_2174_1389201023666220818145350 crossref_primary_10_3390_molecules26133861 crossref_primary_10_3390_ijms23020991 crossref_primary_10_1016_j_livres_2022_05_002 crossref_primary_10_14218_JCTH_2020_00057 crossref_primary_10_1007_s00011_021_01480_z crossref_primary_10_3389_fphar_2020_569575 crossref_primary_10_3390_life13102023 crossref_primary_10_3390_diagnostics13213324 crossref_primary_10_3389_fendo_2022_1002916 crossref_primary_10_12998_wjcc_v10_i31_11240 crossref_primary_10_1002_elsc_202300016 crossref_primary_10_22141_2224_0721_20_2_2024_1373 crossref_primary_10_3390_biomedicines13040779 crossref_primary_10_1097_HC9_0000000000000310 crossref_primary_10_1007_s11901_020_00547_5 crossref_primary_10_3389_fphar_2024_1371574 crossref_primary_10_14218_JCTH_2020_00131 crossref_primary_10_1590_0001_3765202320230037 crossref_primary_10_1371_journal_pone_0250337 crossref_primary_10_1111_jgh_15903 crossref_primary_10_3390_nu15122713 crossref_primary_10_1016_j_cbi_2020_109199 crossref_primary_10_1038_s41467_023_35861_1 crossref_primary_10_3390_medicina59101789 crossref_primary_10_1186_s12876_021_01612_z crossref_primary_10_3389_fcimb_2022_1059647 crossref_primary_10_3389_fmicb_2024_1477187 crossref_primary_10_1038_s41366_023_01375_5 crossref_primary_10_3389_fmed_2022_822190 |
| Cites_doi | 10.1056/NEJMc1004719 10.3945/ajcn.113.068890 10.1126/science.1243787 10.1007/s00394-017-1445-8 10.1111/liv.12957 10.1111/j.1478-3231.2011.02730.x 10.1111/apt.12758 10.1186/1878-5085-5-21 10.1126/science.1241165 10.1371/journal.pone.0151829 10.14670/HH-18-008 10.1097/01.mcg.0000165671.25272.0f 10.1136/gut.34.3.386 10.1038/nrgastro.2010.172 10.3389/fcimb.2018.00013 10.1038/cmi.2016.3 10.1007/s10620-013-2879-3 10.1016/j.cell.2013.12.016 10.1007/s10620-011-1887-4 10.3109/09637486.2013.775224 10.1139/apnm-2012-0261 10.21037/hbsn.2018.12.05 10.3390/nu9101124 10.1016/j.cmet.2017.09.008 10.1186/s12865-016-0187-3 10.1371/journal.pone.0035240 10.5946/ce.2015.117 10.1007/s13679-019-00352-2 10.1136/gutjnl-2015-309990 10.1111/apt.15416 10.1016/j.jnutbio.2010.10.008 10.1016/j.cell.2016.05.041 10.1007/s00018-019-03011-w 10.2337/db08-1637 10.1016/j.cmet.2011.02.018 10.3748/wjg.v23.i19.3565 10.4254/wjh.v9.i16.715 10.4254/wjh.v9.i11.533 10.1016/j.cmet.2019.08.002 10.3748/wjg.v23.i25.4491 10.1002/hep.26321 10.1126/science.1241214 10.1016/j.phrs.2019.01.029 10.1016/S0016-5085(17)33408-X 10.1136/gutjnl-2012-303816 10.1128/IAI.00476-17 10.1007/s00535-017-1415-1 10.1136/gutjnl-2018-316307 10.1002/lt.24754 10.5625/lar.2018.34.4.140 10.1111/j.1365-2036.2012.05220.x 10.20960/nh.02775 10.1016/S0140-6736(57)91544-1 10.1053/j.gastro.2015.04.001 10.3748/wjg.v20.i42.15518 10.1016/j.jhep.2008.01.035 10.1053/j.gastro.2016.06.022 10.3390/nu11112642 10.1136/gutjnl-2019-318320 10.1097/MD.0000000000013543 10.1007/s12275-018-8346-2 10.1053/j.gastro.2006.11.022 10.1210/me.2014-1108 10.3390/nu9091021 10.1073/pnas.0909122107 10.1172/JCI76738 10.1097/MEG.0000000000001232 10.1080/19490976.2019.1674124 10.1038/s41574-019-0266-7 10.3748/wjg.v25.i17.2019 10.1007/s11684-018-0645-9 10.1186/s12906-017-1803-3 10.21037/tgh.2019.06.06 10.1053/j.gastro.2012.06.031 10.1126/science.1198469 10.2337/db05-1360 10.1038/nmicrobiol.2017.75 10.1016/j.ijcard.2016.06.180 10.1038/nri.2016.42 10.1007/s10620-019-05699-z 10.1371/journal.pone.0063388 10.1016/j.mito.2013.10.005 10.1038/ni.2640 10.1038/s41598-017-01751-y 10.1016/j.ijfoodmicro.2004.05.012 10.3390/ijms20184568 10.3390/nu11112837 10.1002/hep.28709 10.1111/1751-7915.13476 10.1177/1756283X11428502 10.2174/138161209788168164 10.1093/jn/132.5.1012 10.1016/j.copbio.2010.03.016 10.1080/17474124.2019.1569513 10.1097/MEG.0000000000000348 10.1016/j.mib.2016.10.003 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. 2020 |
| Copyright_xml | – notice: The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. – notice: The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. 2020 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.3748/wjg.v26.i16.1901 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2219-2840 |
| EndPage | 1911 |
| ExternalDocumentID | PMC7201149 32390701 10_3748_wjg_v26_i16_1901 |
| Genre | Journal Article Review |
| GroupedDBID | --- 123 29R 2WC 36B 53G 5VR 8WL AAKDD AAYXX ACGFO AENEX AFUIB ALMA_UNASSIGNED_HOLDINGS CCEZO CHBEP CIEJG CITATION CS3 CW9 DIK DU5 E3Z EBS EJD F5P FA0 FRP GX1 HYE OK1 P2P RNS RPM TR2 XSB CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c462t-ed47af1f91244db108b7479967fe440fd4d95752b493217e474ce83ac8d186b3 |
| ISSN | 1007-9327 2219-2840 |
| IngestDate | Thu Aug 21 18:21:36 EDT 2025 Fri Jul 11 01:12:02 EDT 2025 Mon Jul 21 06:02:05 EDT 2025 Tue Jul 01 02:11:47 EDT 2025 Thu Apr 24 22:51:45 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 16 |
| Keywords | Gut microbiota Probiotics Metabolites Non-alcoholic fatty liver disease Fecal microbiota transplantation Prebiotics |
| Language | English |
| License | The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c462t-ed47af1f91244db108b7479967fe440fd4d95752b493217e474ce83ac8d186b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 Author contributions: Chen HT performed the majority of the writing; Huang HL performed data acquisition and writing; Li YQ and Xu HM prepared the figure and table and coordinated the writing of the paper; Zhou YJ organized the interpretation of the data and revision of the article. Supported by Guangzhou General Science and Technology Project of Health and Family Planning, No. 20191A011001; Guangzhou Planned Project of Science and Technology, No. 201904010132. Corresponding author: Yong-Jian Zhou, MD, PhD, Professor, Department of Gastroenterology and Hepatology, Guangzhou Institute of Digestive Disease, Guangzhou Medical University, No. 1, Panfu Road, Guangzhou 510180, Guangdong Province, China. yjzhou@gzhmu.edu.cn |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC7201149 |
| PMID | 32390701 |
| PQID | 2401118384 |
| PQPubID | 23479 |
| PageCount | 11 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7201149 proquest_miscellaneous_2401118384 pubmed_primary_32390701 crossref_primary_10_3748_wjg_v26_i16_1901 crossref_citationtrail_10_3748_wjg_v26_i16_1901 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-4-28 2020-Apr-28 20200428 |
| PublicationDateYYYYMMDD | 2020-04-28 |
| PublicationDate_xml | – month: 04 year: 2020 text: 2020-4-28 day: 28 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | World journal of gastroenterology : WJG |
| PublicationTitleAlternate | World J Gastroenterol |
| PublicationYear | 2020 |
| Publisher | Baishideng Publishing Group Inc |
| Publisher_xml | – name: Baishideng Publishing Group Inc |
| References | ref57 ref56 ref59 ref58 ref53 ref52 ref55 ref54 ref51 ref50 ref46 ref45 ref48 ref47 ref42 ref41 ref44 ref43 ref49 ref8 ref7 ref9 ref4 ref3 ref6 ref5 ref40 ref35 ref34 ref37 ref36 ref31 ref30 ref33 ref32 ref39 ref38 ref24 ref23 ref26 ref25 ref20 ref22 ref21 ref28 ref27 ref29 ref13 ref12 ref15 ref14 ref97 ref96 ref11 ref10 ref98 ref17 ref16 ref19 ref18 ref93 ref92 ref95 ref94 ref91 ref90 ref89 ref86 ref85 ref88 ref87 ref82 ref81 ref84 ref83 ref80 ref79 ref78 ref75 ref74 ref77 ref76 ref2 ref1 ref71 ref70 ref73 ref72 ref68 ref67 ref69 ref64 ref63 ref66 ref65 ref60 ref62 ref61 |
| References_xml | – ident: ref29 doi: 10.1056/NEJMc1004719 – ident: ref59 doi: 10.3945/ajcn.113.068890 – ident: ref65 doi: 10.1126/science.1243787 – ident: ref78 doi: 10.1007/s00394-017-1445-8 – ident: ref27 – ident: ref3 doi: 10.1111/liv.12957 – ident: ref56 doi: 10.1111/j.1478-3231.2011.02730.x – ident: ref45 doi: 10.1111/apt.12758 – ident: ref7 doi: 10.1186/1878-5085-5-21 – ident: ref94 doi: 10.1126/science.1241165 – ident: ref16 doi: 10.1371/journal.pone.0151829 – ident: ref2 doi: 10.14670/HH-18-008 – ident: ref46 doi: 10.1097/01.mcg.0000165671.25272.0f – ident: ref86 doi: 10.1136/gut.34.3.386 – ident: ref53 doi: 10.1038/nrgastro.2010.172 – ident: ref97 doi: 10.3389/fcimb.2018.00013 – ident: ref98 doi: 10.1038/cmi.2016.3 – ident: ref41 doi: 10.1007/s10620-013-2879-3 – ident: ref90 doi: 10.1016/j.cell.2013.12.016 – ident: ref60 doi: 10.1007/s10620-011-1887-4 – ident: ref61 doi: 10.3109/09637486.2013.775224 – ident: ref17 doi: 10.1139/apnm-2012-0261 – ident: ref8 doi: 10.21037/hbsn.2018.12.05 – ident: ref24 doi: 10.3390/nu9101124 – ident: ref72 doi: 10.1016/j.cmet.2017.09.008 – ident: ref83 doi: 10.1186/s12865-016-0187-3 – ident: ref89 doi: 10.1371/journal.pone.0035240 – ident: ref63 doi: 10.5946/ce.2015.117 – ident: ref49 doi: 10.1007/s13679-019-00352-2 – ident: ref25 doi: 10.1136/gutjnl-2015-309990 – ident: ref52 doi: 10.1111/apt.15416 – ident: ref55 doi: 10.1016/j.jnutbio.2010.10.008 – ident: ref80 doi: 10.1016/j.cell.2016.05.041 – ident: ref26 doi: 10.1007/s00018-019-03011-w – ident: ref88 doi: 10.2337/db08-1637 – ident: ref91 doi: 10.1016/j.cmet.2011.02.018 – ident: ref71 doi: 10.3748/wjg.v23.i19.3565 – ident: ref5 doi: 10.4254/wjh.v9.i16.715 – ident: ref4 doi: 10.4254/wjh.v9.i11.533 – ident: ref15 doi: 10.1016/j.cmet.2019.08.002 – ident: ref33 doi: 10.3748/wjg.v23.i25.4491 – ident: ref13 doi: 10.1002/hep.26321 – ident: ref64 doi: 10.1126/science.1241214 – ident: ref11 doi: 10.1016/j.phrs.2019.01.029 – ident: ref66 doi: 10.1016/S0016-5085(17)33408-X – ident: ref73 doi: 10.1136/gutjnl-2012-303816 – ident: ref84 doi: 10.1128/IAI.00476-17 – ident: ref21 doi: 10.1007/s00535-017-1415-1 – ident: ref18 doi: 10.1136/gutjnl-2018-316307 – ident: ref75 doi: 10.1002/lt.24754 – ident: ref96 doi: 10.5625/lar.2018.34.4.140 – ident: ref68 doi: 10.1111/j.1365-2036.2012.05220.x – ident: ref57 doi: 10.20960/nh.02775 – ident: ref28 doi: 10.1016/S0140-6736(57)91544-1 – ident: ref76 doi: 10.1053/j.gastro.2015.04.001 – ident: ref37 doi: 10.3748/wjg.v20.i42.15518 – ident: ref30 doi: 10.1016/j.jhep.2008.01.035 – ident: ref14 doi: 10.1053/j.gastro.2016.06.022 – ident: ref38 doi: 10.3390/nu11112642 – ident: ref70 doi: 10.1136/gutjnl-2019-318320 – ident: ref69 doi: 10.1097/MD.0000000000013543 – ident: ref22 doi: 10.1007/s12275-018-8346-2 – ident: ref54 doi: 10.1053/j.gastro.2006.11.022 – ident: ref95 doi: 10.1210/me.2014-1108 – ident: ref36 doi: 10.3390/nu9091021 – ident: ref92 doi: 10.1073/pnas.0909122107 – ident: ref23 doi: 10.1172/JCI76738 – ident: ref32 doi: 10.1097/MEG.0000000000001232 – ident: ref20 doi: 10.1080/19490976.2019.1674124 – ident: ref79 doi: 10.1038/s41574-019-0266-7 – ident: ref12 doi: 10.3748/wjg.v25.i17.2019 – ident: ref10 doi: 10.1007/s11684-018-0645-9 – ident: ref39 – ident: ref58 doi: 10.1186/s12906-017-1803-3 – ident: ref9 doi: 10.21037/tgh.2019.06.06 – ident: ref67 doi: 10.1053/j.gastro.2012.06.031 – ident: ref93 doi: 10.1126/science.1198469 – ident: ref51 doi: 10.2337/db05-1360 – ident: ref85 doi: 10.1038/nmicrobiol.2017.75 – ident: ref1 doi: 10.1016/j.ijcard.2016.06.180 – ident: ref81 doi: 10.1038/nri.2016.42 – ident: ref62 doi: 10.1007/s10620-019-05699-z – ident: ref40 doi: 10.1371/journal.pone.0063388 – ident: ref34 doi: 10.1016/j.mito.2013.10.005 – ident: ref77 doi: 10.1038/ni.2640 – ident: ref74 doi: 10.1038/s41598-017-01751-y – ident: ref44 doi: 10.1016/j.ijfoodmicro.2004.05.012 – ident: ref47 doi: 10.3390/ijms20184568 – ident: ref35 doi: 10.3390/nu11112837 – ident: ref19 doi: 10.1002/hep.28709 – ident: ref42 doi: 10.1111/1751-7915.13476 – ident: ref48 doi: 10.1177/1756283X11428502 – ident: ref50 doi: 10.2174/138161209788168164 – ident: ref87 doi: 10.1093/jn/132.5.1012 – ident: ref43 doi: 10.1016/j.copbio.2010.03.016 – ident: ref6 doi: 10.1080/17474124.2019.1569513 – ident: ref31 doi: 10.1097/MEG.0000000000000348 – ident: ref82 doi: 10.1016/j.mib.2016.10.003 |
| SSID | ssj0023352 |
| Score | 2.461324 |
| SecondaryResourceType | review_article |
| Snippet | Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent metabolic disorder with steadily increasing incidence rates worldwide, especially in the West.... |
| SourceID | pubmedcentral proquest pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 1901 |
| SubjectTerms | Animals Anti-Bacterial Agents - administration & dosage Clinical Trials as Topic Combined Modality Therapy - methods Disease Models, Animal Dysbiosis - complications Dysbiosis - immunology Dysbiosis - microbiology Dysbiosis - therapy Fecal Microbiota Transplantation Gastrointestinal Microbiome - drug effects Gastrointestinal Microbiome - immunology Humans Intestinal Mucosa - drug effects Intestinal Mucosa - immunology Intestinal Mucosa - metabolism Intestinal Mucosa - microbiology Minireviews Non-alcoholic Fatty Liver Disease - immunology Non-alcoholic Fatty Liver Disease - metabolism Non-alcoholic Fatty Liver Disease - microbiology Non-alcoholic Fatty Liver Disease - therapy Prebiotics - administration & dosage Probiotics - administration & dosage Synbiotics - administration & dosage Treatment Outcome |
| Title | Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/32390701 https://www.proquest.com/docview/2401118384 https://pubmed.ncbi.nlm.nih.gov/PMC7201149 |
| Volume | 26 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELdgvPCCmPjqYMhIvCDkbIndJOVtmjZVUxlCSkV5spzELkEjRVsKEn89d_7ImlGhwUsUOY5j3f1yvrPvg5DXwOZqXAnDYHE3TBg-ZqCFCCZ4bmpYYKvS2Gyf5-l0Ls4W48X1VraNLunKqPq1Na7kf7gKbcBXjJL9B872g0ID3AN_4QochutteRyCp8JhvnVvBZOeKVf7Fp4Y1WF5CHTACOcxLh79W-OyMHWKoY8mVu18258UeIXVOdts5JdYqqvucmW7u_RNONans75E17EP95iuG1aEddHixu9MT1ftks2a3hPIuhN8xsaPANW-_2JtO6sVex9G8ZsTCXqKhmBvK8MSEIjQ4DIyRXpLmxfCLmw-gG1TpKLGsk3WY94cYNDPr8voR5JGTZxGoeswrfb5B3k6n81kcbIo7pJ7CdgTPGzreMscA8-wCmGYmTvPxi8c3Bx_qL_8YZTc9K3dUFaKh-SBtzLokYPMLrmj20dkvgEXGuBCm5YO4EItXKiFC_VweUeP6BawUATLY1KcnhTHU-ararBKpEnHdC0yZWIzQc2uLuPDvASTEszezGghDk0t6gno8EkpQLWPMy0yUemcqyqv4zwt-ROyA9PSzwhFZa9MjcrTDP72jKtxxRNVYs2BGAS7GpGDQCpZ-YzzWPjkQoLlicSVQFwJxJVAXInEHZE3_RvfXbaVv_R9FagvQSTiOZdq9Wp9JUFJhQnkPBcj8tRxox-NJ3wCqxy8nQ341HfAdOvDJ23zxaZdz1BXFpO9W3z3Obl__Te8IDvd5Vrvg_LalS8t8H4DvmicsA |
| linkProvider | National Library of Medicine |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Therapeutic+advances+in+non-alcoholic+fatty+liver+disease%3A+A+microbiota-centered+view&rft.jtitle=World+journal+of+gastroenterology+%3A+WJG&rft.au=Chen%2C+Hui-Ting&rft.au=Huang%2C+Hong-Li&rft.au=Li%2C+Yong-Qiang&rft.au=Xu%2C+Hao-Ming&rft.date=2020-04-28&rft.issn=2219-2840&rft.eissn=2219-2840&rft.volume=26&rft.issue=16&rft.spage=1901&rft_id=info:doi/10.3748%2Fwjg.v26.i16.1901&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1007-9327&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1007-9327&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1007-9327&client=summon |